Drugmaker Eli Lilly and Co. spent nearly $3.6 million in the second quarter lobbying the federal government on health care
reform and trademark issues, among other topics, according to a recent disclosure form.
lobbied on patent reform, intellectual property rights, anti-counterfeiting measures, drug importation and comparative effectiveness
research, as plans to curb health care spending and cover the uninsured were debated in Congress.
Lilly also lobbied
about tax deferrals and antibiotic legislation for animals, according to a report filed July 20 with the House clerk’s office.
Besides Congress, Lilly lobbied the Food and Drug Administration, Federal Trade Commission, Patent and Trademark Office,
U.S. Trade Representative, National Security Council, and the departments of Agriculture, Commerce, State and Treasury.
Among those lobbying on Lilly’s behalf in the April-June period were J. Savonne Caughey, former senior adviser to
the undersecretary for the Department of Agriculture.
Lilly’s second-quarter total represented a 26-percent increase
from the $2.9 million it spent in the same quarter last year.